ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Molecular and pharmacological interference with SK-1/S1P2 may restore PP2A-dependent dephosphorylation and enhance IM- or nilotinib-induced growth inhibition in primary CD34+ CML progenitors and BCR–ABL1+ cell lines.